drugset / Trial / NCT07628972

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)

NCT07628972

Phase 1 Recruiting 12 enrolled Children's Hospital Medical Center, Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).

Timeline

Start
2026-05-29
Primary completion
2028-09
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quercetin Small molecule 4000 mg Oral